TABLE 1.
Patient demographics.
| Patient demographics (n and %) |
Overall n = 90 (100) |
miR-125b ≤ 4.6 n = 63 (70) | miR-125b > 4.6 n = 27 (30) | P-value |
| miR-125b | 4.1 ± 1.0 | 3.6 ± 0.7 | 5.7 ± 1.0 | <0.001 |
| Age (years) Sex (male), n (%) |
60.9 ± 11.1 77 (86) |
60.2 ± 10.5 57 (91) |
62.5 ± 12.6 20 (74) |
0.395 0.043 |
| Risk factors/past medical history n (%) | ||||
| Body mass index | 27.4 ± 5.5 | 27.1 ± 4.5 | 28.1 ± 7.4 | 0.090 |
| Arterial hypertension | 63 (70) | 43 (68) | 20 (77) | 0.413 |
| Dyslipidemia | 51 (57) | 36 (57) | 15 (58) | 0.962 |
| Diabetes mellitus | 30 (33) | 23 (37) | 7 (27) | 0.384 |
| Peripheral artery disease | 4 (4) | 2 (3) | 2 (8) | 0.350 |
| Cerebrovascular disease | 5 (6) | 4 (6) | 1 (4) | 0.641 |
| Chronic obstructive pulmonary disease | 4 (4) | 4 (6) | 0 (0) | 0.180 |
| Smoking | 68 (76) | 50 (79) | 18 (69) | 0.306 |
| Family history of CAD | 40 (44) | 30 (48) | 10 (39) | 0.430 |
| Prior myocardial infarction | 26 (29) | 20 (32) | 6 (23) | 0.413 |
| Prior PCI | 17 (19) | 14 (23) | 3 (12) | 0.231 |
| Laboratory data (mean ± SD) | ||||
| White blood cell count (x109/L) | 10.6 ± 3.6 | 10.6 ± 3.6 | 10.8 ± 3.5 | 0.761 |
| Platelets (x109/L) | 230.9 ± 57.3 | 228.1 ± 56.1 | 237.4 ± 60.6 | 0.657 |
| Hemoglobin (g/dL) | 14.2 ± 1.7 | 14.3 ± 1.8 | 14.0 ± 1.5 | 0.451 |
| C-reactive protein (mg/dL) | 3.4 ± 4.1 | 2.9 ± 3.6 | 4.6 ± 4.9 | 0.048 |
| Fibrinogen (mg/dL) | 405.2 ± 104.8 |
393.2 ± 102.0 |
432.3 ± 107.5 |
0.137 |
| Creatinine (mg/dL) | 1.0 ± 0.2 | 1.0 ± 0.2 | 1.0 ± 0.3 | 0.405 |
| Troponin T (μg/L) | 0.6 ± 1.4 | 0.7 ± 1.6 | 0.5 ± 0.7 | 0.680 |
| HbA1c (%) | 6.2 ± 1.3 | 6.2 ± 1.3 | 6.3 ± 1.3 | 0.409 |
| GFR (ml/min/1.73 m2) | 79.7 ± 19.5 | 80.2 ± 19.7 | 78.4 ± 19.2 | 0.968 |
| Concomitant medication n (%) | ||||
| Aspirin | 90 (100) | 63 (100) | 27 (100) | |
| Clopidogrel | 2 (2) | 2 (3) | 0 (0) | 0.360 |
| Ticagrelor | 38 (42) | 26 (43) | 12 (48) | 0.648 |
| Prasugrel | 46 (51) | 33 (54) | 13 (52) | 0.859 |
| ß-blockers | 79 (88) | 56 (90) | 23 (89) | 0.793 |
| Angiotensin converting enzyme (ACE) inhibitors/Angiotensin II receptor blockers (ARB) | 78 (87) | 45 (87) | 24 (92) | 0.482 |
| Calcium channel-blockers | 14 (16) | 9 (15) | 5 (19) | 0.581 |
| Proton pump Inhibitors (PPI) | 70 (78) | 49 (79) | 21 (81) | 0.854 |
| Statins | 84 (93) | 59 (95) | 25 (96) | 0.838 |
| Antidiabetic drugs | 25 (28) | 19 (31) | 6 (23) | 0.473 |
| ACS data | ||||
| NSTE-ACS | 26 (29) | 17 (27) | 9 (33) | 0.543 |
| STEMI | 64 (71) | 46 (43) | 18 (67) | 0.543 |
| Number of stents per patient | 1.9 ± 1.3 | 1.8 ± 1.2 | 2.1 ± 1.4 | 0.385 |
| Total stent length | 44.4 ± 29.1 | 43.7 ± 31.4 | 46.2 ± 23.0 | 0.346 |
Data are reported as mean ± standard deviation (SD), n (number of patients) or percentages; miR, microRNA; CAD, coronary artery disease; HbA1c, glycated hemoglobin; GFR, glomerular filtration rate; PCI, percutaneous coronary intervention, STEMI, ST-elevation myocardial infarction; NSTE-ACS, non-ST-segment elevation acute coronary syndrome. Bold p-values indicate statistical significance.